This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 29, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that its COO,
Anthony Maida III, Ph.D., MA, MBA, will be presenting at the Cancer Immunotherapy Conference as the lead afternoon speaker at 1:45 pm ET on
Wednesday, February 29, 2012, in
Boston, Massachusetts at the Metro Meeting Center at 101 Federal Street.
Dr. Maida's presentation, entitled "
DevelopingImmune Therapies with Multiple Complementary Product Lines," will address the various components of developing a dendritic cell vaccine based on a patient's own tumor tissue. Using NW Bio's DCVax®-L vaccine platform technology for solid tumor cancers as an example, Dr. Maida will discuss the identification of clinically relevant tumor antigens (biomarkers), clinical trial design, assessment of immune response and clinical efficacy, and tumor evasion tactics. In addition, Dr. Maida will address manufacturing with scale-up strategies, and commercial development of active immune therapies.
The three day conference on this rapidly expanding field of future cancer treatment potential is directed at featuring "industry innovators blazing a trail towards successful and sustained commercialization." Dr. Maida's longstanding experience in the field and NW Bio's progress to date will be presented in support of the Conference's key theme of "Re-engineering the Immune System for Effective Management of Cancer."
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the US and Europe.
The Company has a broad platform technology for dendritic cell-based vaccines. The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal brain cancer. In the earlier Phase I/II clinical trials for GBM brain cancer, patients who received DCVax® showed a median survival of 3 years compared with median survival of 14.6 months for patients who received standard of care (surgery, radiation and chemotherapy). Patients who received DCVax® also experienced a substantially longer time to tumor recurrence: a median of 2 years, compared with 6.9 months in patients who received standard of care. DCVax® was well-tolerated, with no toxic side effects.